Friday, 29 July 2011

U.S. Analyst: 12-month Neptune Shares at $9

Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million


Roth Capital Partners, an influential U.S.-based firm especially in the biotech space, issued its initiating analyst report on Neptune Technologies today with a BUY recommendation and 12-month target price of $9.

Given that Neptune closed yesterday at $4.03, that's a hefty premium.

The author of the report is Joseph Pantginis, received an M.B.A. in Finance from Pace University; a Ph.D. in Molecular Genetics and an M.S. from Albert Einstein College of Medicine; and a B.S. from Fordham University.
And rather than pull out highlights from his report, please click here to read it all.